With 'rapid' progress of pediatric brain cancer treatment, Day One sees broad excitement in new crossover round
Roughly nine months after emerging from stealth, Day One Biopharmaceuticals returned to the venture capital well and came away with a nine-figure prize. And with the hefty crossover round, it raises the big question of whether they’re prepping an S-1 to enter a hot biotech IPO market.
Day One raised $130 million in a Series B, the biotech announced Wednesday, with the funding led by RA Capital. The funds will help support a variety of pipeline projects, including the development of their lead compound DAY101 in preparation for a potential commercial launch in 2023.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
